CS Paper Radar

Accelerating the Development of PLGA In Situ Forming Depots Through AI-Driven Multi-Objective Optimization

Pauric Bannigan, Siddarth Chandrasekaran, Brigitte A. G. Lamers, Inge Hermsen, Gary Tom, Riley J. Hickman, Bahar Yeniad, Morgan Fox, Christine Allen

cs.LG cs.AI ·submitted 2026-10-06 13:54 UTC · v1
unusual

Abstract

Developing long-acting injectable formulations requires the simultaneous optimization of drug loading, release kinetics, viscosity, injectability, stability and other objectives. To navigate this multidimensional space, Corbion and Intrepid combined Corbion's diverse PURASORB bioresorbable polymer library with Intrepid Labs' proprietary AI algorithm (ANDROMEDA 1) to develop in situ forming depots for a therapeutic peptide. Over approximately 15 weeks, 181 unique formulations spanning drug loadings of 6-12% w/w were prepared and characterized through broad design-space mapping and targeted multi-objective optimization. Four lead candidate formulations were identified at 6%, 9%, and 12% w/w drug loading. Each met the predefined viscosity and injectability criteria while providing distinct 30-day in vitro release profiles. The study evaluated polymers spanning a broad range of molecular weights, including commercially available PURASORB grades and new polymers under development by Corbion to expand its polymer toolbox. ANDROMEDA 1 identified that polymers with intermediate molecular weights provided a favorable balance between sustained release and solution viscosity. Together, these findings demonstrate how integrated polymer expertise and AI-driven optimization can rapidly identify differentiated formulation candidates, focus the development space, and establish a strong data-driven foundation for further optimization and in vivo evaluation.

Comment
10 pages; 7 figures

Closest papers

Nearest neighbours by meaning across the whole index.

CupOFMoCA: Coupled Objective-Guided Discrete Flows for Molecular Conjugate Assembly

cs.LG q-bio.BM ·2026-11-11 ·Ruoxi Rosie Zhang, Ziang Li, Jiatao Gu, Pranam Chatterjee
top venue similarity 0.55
Abstract · Published at NeurIPS 2026. (Proceedings of the 40th Conference on Neural Information Processing Systems, Sydney, Australia)

Molecular conjugates, including PROTACs and peptide-drug conjugates (PDCs), derive their function from the joint behavior of multiple coupled components, yet most generative approaches design these components independently and combine them only after generation. Such staged pipelines ignore cross-component dependencies and often produce conjugates that are chemically invalid, fall outside empirical conjugate distributions, or lose function upon assembly. In this work, we introduce Coupled Objective-Guided Discrete Flows for Molecular Conjugate Assembly (CupOFMoCA), a discrete generative method that enforces cross-component chemical constraints during conjugate generation. CupOFMoCA restricts guided updates to chemically feasible conjugate states and reweights local transitions using molecular design objectives. Across three PDC systems, coupled generation achieved 100% conjugation validity among valid peptides and increased valid yield over matched post-hoc filtering, with comparable predicted binding scores across the full valid sets. In three-seed evaluations of three PROTAC systems, CupOFMoCA achieved the highest assembly validity on two systems and generated more assembly-valid molecules per second than the evaluated baselines. We further evaluated the generated PROTACs with post-hoc DegradeMaster scoring and explicit-solvent molecular dynamics, supporting their predicted activity and conformational properties. Together, these results establish CupOFMoCA as an efficient generator of molecular conjugates, supporting therapeutic development via coordinated control of assembly and molecular properties.

0.36

Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory

cs.LG ·2026-09-16 ·Michael M. Craig, Riley J. Hickman, Yingshan Ma, Rémi Piché-Taillefer, Christine Allen +1 more
benchmark similarity 0.50
Abstract

Self-emulsifying drug delivery systems (SEDDS) can improve the oral bioavailability of poorly soluble drugs, but identifying high-performing formulations remains experimentally intensive. We present Andromeda 2, an agentic system that reasons over structured in-house experimental evidence and invokes computational and experimental tools to design and execute successive formulation batches. Using a miniaturized automated laboratory at a matched budget, we benchmark it against Andromeda 1, a probabilistic optimization model deployed across dozens of live development projects, and a wet-lab design-of-experiments (DoE) campaign. For paclitaxel, Andromeda 2 achieved a 50% high-performance hit rate versus 17% for Andromeda 1 and 2% for DoE, and identified 12 formulations meeting all four target product profile (TPP) objectives versus 6 and 0, respectively. Median $AUC_{10-240}$ was 70.1, 12.0, and 3.5 mg$\cdot$min/mL, while maximum AUC was comparable between Andromeda 2 and Andromeda 1. A selected full-TPP formulation achieved an apparent effective paclitaxel loading of $19 \pm 5\%$ w/w at the first FaSSIF measurement, approximately 3.3-fold higher than the 5.7% w/w loading reported for a published paclitaxel S-SEDDS. A controlled ablation showed that access to structured in-house experimental evidence increased mean AUC by 34%.

0.31

Decoding Extrahepatic Targeting of Lipid Nanoparticles with Interpretable Machine Learning

cs.CE q-bio.QMcs.LG ·2026-09-15 ·Asal Mehradfar, Mohammad Shahab Sepehri, Owen Antholine, Varun Shankar, Glen S. Kwon +2 more
similarity 0.50
Abstract

Lipid nanoparticles (LNPs) have transformed RNA medicine, yet their clinical utility remains constrained by predominant hepatic accumulation after systemic administration. Redirecting LNPs to extrahepatic tissues requires understanding of how lipid chemistry and formulation composition jointly govern in vivo biodistribution. Here, we develop an interpretable machine learning framework to predict hepatic versus extrahepatic LNP accumulation and identify molecular design rules for extrahepatic RNA delivery. A literature-derived dataset of 476 intravenous LNP formulations was curated from 81 studies, integrating formulation composition, lipid chemical structures, and IVIS-based biodistribution profiles. Standardized SMILES representations of ionizable lipids, helper lipids, sterols, PEGylated or polymer-conjugated lipids, additional lipids, and polymer repeat units were converted into RDKit Expert descriptors and combined with formulation-level variables to generate an 808-dimensional feature representation. Logistic regression, random forest, and XGBoost achieved ROC-AUC values of 0.839, 0.866, and 0.874, respectively. SHAP-based interpretation and consensus feature ranking revealed that ionizable-lipid descriptors dominate biodistribution prediction, while formulation composition, particularly ionizable lipid, sterol, and PEGylated/polymer-conjugated lipid fractions, contributes substantially. The top 20 consensus features retained nearly all predictive information in tree-based models. The most informative features implicated electrotopological surface properties, charge- and hydrophobicity-weighted surface areas, molecular topology, and amide/alkyl structural motifs as drivers of extrahepatic accumulation. This study establishes an interpretable, data-driven strategy for decoding LNP biodistribution and provides actionable design principles for engineering LNPs beyond the liver.

0.24

PeptSol: A Translational Benchmark for Protected-Peptide Solubility in Drug Manufacturing

cs.LG physics.chem-phq-bio.BM ·2026-10-31 ·Alexander Arjun Lobo, Marc Saouda, Urvi Awasthi, Leonid Zhukov
publishedbenchmark similarity 0.48
Abstract · 15 pages, 1 figure, 19 tables. Accepted at the AI for Drug Discovery workshop, NeurIPS 2026

Liquid-phase peptide synthesis (LPPS) offers a scalable route to peptide manufacturing, but route development still depends on empirical solvent screens because each protected intermediate must be soluble for reaction and recoverable for purification. The protecting groups, terminal modifications, and noncanonical residues that govern this behaviour are poorly represented in existing peptide property benchmarks, limiting the ability to develop and rigorously evaluate molecular representation models for LPPS-relevant prediction tasks. We introduce PeptSol, an open benchmark of 1388 hand-curated protected-peptide solubility measurements with chemistry-aware splits. The measurements span only 84 parent sequences and 101 protected structures, and 92.5% come from a single historical programme. Across seven frozen molecular encoders, the best macro-F1 is 0.843 on binary solubility for the historical subset under a peptide-held-out split; the harder three-class ordinal task reaches 0.614 in that cell. No foundation model consistently outperforms a baseline combining chemical fingerprints with explicit molecular descriptors, and model rankings vary across prediction tasks and data splits. The dataset, evaluation protocol, and baselines establish a standard for measuring progress on molecular representations for synthesis-aware peptide developability.

0.31

Geometry-Dependent Properties of Physically Crosslinked PPy-PVA Hydrogels Enable Tunable Iontophoretic Drug Delivery

cs.RO physics.med-ph ·2026-10-22 ·Heather Jin Hee Kim, Mohsen Alishahi, Kyuin Park, Mikaila K. Roncevich, Larissa M. Shepherd +1 more
top venueunusual similarity 0.47
Abstract

Objective: Iontophoretic drug delivery has primarily relied on current modulation to regulate drug transport. Here, we investigate hydrogel geometry, microstructure, and local electric fields as alternative mechanisms for controlling transdermal delivery. Methods: Bovine serum albumin (BSA) was encapsulated in polypyrrole-polyvinyl alcohol (PPy-PVA) hydrogels. Five geometries, including Hilbert curve-based designs, were fabricated to vary pore architecture and local electric field distributions. We optimized PPy content, drug loading, and current density. Electric fields were evaluated using finite element analysis, and microstructures were characterized by scanning electron microscopy. Drug transport was assessed using Franz diffusion cells with artificial membranes. Results: Hydrogel geometries exhibited distinct microstructures and electric field distributions. Iontophoresis substantially enhanced permeability compared with passive diffusion, while individual geometries produced different cumulative release, flux, and permeability profiles. The average iontophoretic permeability was (3.80 +/- 1.93) x 10^-5, exceeding previously reported values using artificial membranes. Conclusion: Geometry-driven fabrication of drug-loaded hydrogels enables tunable transport characteristics under both iontophoretic and passive conditions. Significance: Geometry-mediated control offers an alternative approach to regulating iontophoretic drug delivery without requiring individual current-density modulation.

0.38

One Sequence, Many Decodings: CAGenMol-2 Recasts Drug Design as Masked Molecular Inference

cs.LG cs.AI ·2026-09-28 ·Yanting Li, Enyan Dai, Lei Wang, Wen-Cai Ye, Li Liu
similarity 0.47
Abstract

Drug design couples property evaluation, conditional generation, structure-based design, and local optimization, yet machine learning systems typically address these capabilities with separate task-specific models. We introduce CAGenMol-2, a masked diffusion molecular language model that represents molecules, continuous scalar properties, and 3D protein pockets within a single wrapped sequence. Within this pretrained interface, downstream operations are selected by which sequence regions are observed or masked at inference, allowing one checkpoint to perform property prediction, property- and pocket-conditioned generation, and partial-constraint design without task-specific architectures or backbone fine-tuning. We further propose Adaptive Fragment Optimization (AdaFO), a gradient-free mask-and-refill search that turns the masked decoder into an iterative local molecular optimizer. On CrossDocked2020, AdaFO increases Success Rate from 30.2\% to 70.8\%, the best reported under this protocol, while largely preserving drug-likeness and diversity. Finally, scaffold-preserving directional editing and CRBN/VHL case studies demonstrate its use in compound design workflows spanning local molecular editing, structure-based prioritization, and downstream simulation-based screening.

0.15

The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design

cs.AI q-bio.QMcs.LG ·2026-11-10 ·Maria Franz, N. Benjamin Erichson
published similarity 0.47
Abstract · 14 pages, 3 figures. Accepted at the AI4DD workshop (AI for Drug Discovery: Bridging the Translation Gap), NeurIPS 2026

Generative models are increasingly used to propose molecules for drug discovery. They can produce far more candidates than can be experimentally tested, making computational selection essential. Most selection methods rely on predicted molecular properties, such as potency and toxicity, but overlook how these properties translate into drug exposure at a given dose. As a result, molecules that appear promising on paper may require impractical doses or raise safety concerns. We investigate this gap by using physiologically based pharmacokinetic (PBPK) simulations to re-evaluate molecules selected from three PARP1-targeted generative pipelines. Of 60 shortlisted molecules, seven fail to achieve sufficient target exposure, while 28% of the remaining candidates show predicted safety risks at their required dose. Moreover, 85% of candidates with an achievable dose are outperformed by molecules overlooked during static selection. These findings suggest that accounting for dose and exposure can substantially change which generated molecules are considered promising for drug development.

0.40

A Modular Agentic Framework for Synthetically Constrained Multi-Objective Hit-to-Lead Optimization

cs.AI cs.LGq-bio.QM ·2026-08-11 ·Kelvin P. Idanwekhai, Enes Kelestemur, Benjamin Strickland, Matthew Hart, Steini Davidsson +4 more
code/data similarity 0.47
Abstract · 22 pages, 9 figures

Hit-to-lead optimization requires iterative design of hit analogs across competing potency, selectivity, physicochemical, pharmacokinetic, safety, and synthetic constraints. We present SABLE (Synthetically-accessible Agentic Bayesian Ligand Exploration), an open-source framework that employs natural-language orchestration to guide chemical structure optimization. SABLE uses an LLM to interpret user-defined goals and route tasks, while specialized tools perform reaction-templated analog enumeration, physicochemical and ADMET property prediction, structure-based affinity scoring, and Bayesian optimization. The resulting workflow is a computational twin of the analytical and prioritization stages of the design-make-test-analyze cycle, providing provenance of each numerical output. Across single, and multi-objective optimization studies, SABLE enriches candidate sets for user-defined computational objectives while evaluating only a subset of the enumerated search space. Its modular architecture allows tools and characterization backends to be replaced by editing a simple config file, without modifying operational logic. SABLE provides an extensible decision-support framework for prioritizing synthetically constrained analogs in early-stage drug discovery.

0.26